Bringing hope through science
Monica Shaw appointed CEO
On January 4, 2023, Oncopeptides announced that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately.
Jakob Lindberg interviewed by Di.TV regarding the leadership change
On Wednesday January 4, Jakob Lindberg was interviewed by by the Swedish economy TV channel Di.TV regarding the announced leadership change in Oncopeptides. Jakob Lindberg comments on his resignation as CEO of Oncopeptides and the appointment as Chief Scientific Officer.
Press release -
Oncopeptides Chief Financial Officer Holger Lembrer takes office today
Read press release
Upcoming events
-
-
-
08:00 CET
-
-
-
Released
Interim report Q3 2022
”Oncopeptides enters a new phase with EMA approval and launch of Pepaxti in Germany as the first market”
CEO Jakob Lindberg
See the Webcast
For further information, please contact:
Rolf Gulliksen
Global Head of Corporate Communications
Year-end report 2022,
February 16, 2023
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
CEO Jakob Lindberg interviewed by Di.TV regarding the Q3 report and the EU and US market
On November 9, 2022, CEO Jakob Lindberg was interviewed by Börsmorgon in the Swedish Dagens Industri Di.TV regarding the Q3 report and the EU and US market. See the interview by clicking the link below. The interview is in Swedish.
Tyska lanseringen av Pepaxti - presentation
Fredagen den 21 oktober kl.14.00, 2022, håller Oncopeptides en presskonferens för att prata om den tyska lanseringen av Pepaxti®.
Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU
June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.
Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor.
Released
Annual Report 2021
Rolf Gulliksen
Global Head of Corporate Communications
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
Letter from the CEO - Science is leading the way
"When I look back at 2021, this has been the most revolutionary year in Oncopeptides’ history"
Jakob Lindberg, CEO
Jakob interviewed by Di.TV - as new CEO about going forward
In conjunction with the anouncement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.
Jakob Lindberg appointed CEO
On November 15, Oncopeptides announced that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides. Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
Read more
Vision of Oncopeptides
“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
Cultures & Values
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.